Suggested remit: To appraise the clinical and cost effectiveness of tezepelumab within its marketing authorisation for treating severe asthma.
Status In progress
Decision Selected
Process STA 2018
ID number 3910

Provisional Schedule

Committee meeting: 1 08 November 2022

Project Team

Project lead Jeremy Powell

Email enquiries

External Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics, University of York


Companies sponsors AstraZeneca
Others Department of Health and Social Care
  NHS England
  NHS Leeds South and East CCG
  NHS Salford CCG
  Welsh Government
Patient carer groups Allergy UK
  Asthma Relief Charity
  Asthma Trust for Asthmatic Children
  Asthma UK
  British Lung Foundation
  NARA – The Breathing Charity
  South Asian Health Foundation
  Specialised Healthcare Alliance
  The Samter’s Society
  South Asian Health Foundation
  Specialised Healthcare Alliance
Professional groups Association for Respiratory Technology and Physiology
  Association of Respiratory Nurse Specialists
  British Geriatrics Society
  British Paediatric Respiratory Society
  British Society for Allergy & Clinical Immunology
  British Thoracic Society
  National Heart and Lung Institute
  Neonatal Paediatric Pharmacy Group
  Primary Care Respiratory Society UK
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  UK Clinical Pharmacy Association
Associated public health groups UK Health Security AgencyPublic Health Wales
Comparator companies AstraZeneca (benralizumab)
  GlaxoSmithKline (mepolizumab)
  Novartis Pharmaceuticals (omalizumab)
  Sanofi Genzyme (dupilumab)
  Teva Pharmaceuticals (reslizumab
General commentators Allied Health Professionals Federation
  All Wales Therapeutics and Toxicology Centre
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Asthma, Allergy and Inflammation Research Trust
  British Association for Lung Research
  Cochrane Airways Group
  Cochrane UK
  MRC Clinical Trials Unit
  National Institute for Health Research


Key events during the development of the guidance:

Date Update
22 March 2022 NICE has received a request from the company to delay the evaluation of tezepelumab for treating severe asthma, to allow them time collect further information to support their submission of evidence. The committee meeting is now scheduled for Tuesday 8 November 2022.
29 November 2021 Invitation to participate
29 November 2021 In progress. ITP
22 April 2021 - 21 May 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual